Radiomics.bio
Insight-based
decision making
Diseases and
therapeutic areas
Industry
and Pharma
Healthcare
professionals
Scientific
researchers
About Radiomics.bio
We can help you
Optimise
Your clinical trials (in terms of costs and time)
Detect
Facilitate
go / no-go
decisions
Identify
Strengthen
in pay for outcome scenarios
Why Radiomics.bio
Experience
Outreach
Radiomics.bio has clients and partners in the EU, the US, Africa and Australia. Radiomics has a permanent presence in North America with a fully owned affiliate in Toronto.
IP Portfolio
Radiomics.bio's comprehensive IP portfolio includes both granted and pending international (EU/US) patents.
People
Radiomics.bio's team is composed of a multicultural and multidisciplinary set of people, specialized in a broad range of domains always enthusiastic in addressing clients and partner's needs.
Publications
Radiomics.bio has numerous publications in high impact journals such as Nature Reviews, Clinical Oncology, Annals of Oncology and many more.
Latest news
- February 29th, 2024
From Images to Impact: Radiomics' Solutions to Challenges in Immunotherapy
Up to 30% of patients may experience hyper progression following immunotherapy. Identifying patients who will actually benefit from immunotherapy is intrinsic to achieving optimal outcomes. Radiomics can offer a solution to this problem by analysing the phenotypical changes in lesions and organs that may occur following the initiation of a treatment.
- September 5th, 2023
Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients
Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients
- April 7th, 2023
Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy
DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment.